Back

PCSK9 inhibitors: the story continues.

27 August 2017 (18:30 - 18:40)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention Endothelial function Open Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

2 More presentations in this session

Presentation thumbnail
Challenging the data.
Professor J. Chapman (Paris, FR) Professor P. Sever (London, GB)
Presentation thumbnail
PCSK9 inhibitors: more volumes to come?
Professor J. Chapman (Paris, FR)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

The Event

Event poster

ESC Congress 2017

27 August 2017 18:30 CET
You may be interested in
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources